Positive CUE-221 Phase 2 CSU results lift Cue Biopharma in pre-market
- Cue Biopharma issued Sunday 6 AM ET GlobeNewswire release on CUE-221 Phase 2 CSU data.
- Primary endpoint of complete hive resolution at week 12 met at all three doses versus placebo.
- Highest 4 mg/kg dose showed 54% HSS7=0 and 46% UAS7=0 complete response versus 11% placebo.
- Favorable safety with no treatment-related SAEs; durability seen 12 weeks off therapy.
- Results support advancing to Phase 2b/3 CSU study and food allergy development.
- Announcement came after Friday close, so first reaction is Monday pre-market.
- B. Riley Buy initiation Friday with $83 target noted CUE-221 as near-term catalyst.
- Company hosts 8 AM ET conference call today to discuss the data.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.